ANEB

15-12G - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

25 - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

SCHEDULE 13G/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

10-Q - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the "Board") approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to t

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Company's board of directors (the "Board") has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to terminate and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Simultaneously with this announcement, Anebulo notified Na

SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the final count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,907,881 shares of Common Stock were properly tendered and not properly withdrawn. The tender offer was oversubscribed. In

SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the preliminary count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,897,188 shares of Common Stock were properly tendered and not properly withdrawn, excluding 10,868 shares that w

SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

SC TO-I - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

SC TO-I - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to "go private" in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Voluntary Self Tender consists of acquiring up to 300,000 shares at $3.50 price per share While the Board of Directors believed that the reverse stock split transaction was in the best interest of the Company and its stockholders at t

10-Q - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2025, and recent updates. First Quarter Fiscal Year 2026 and Subsequent Highlights: On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety, tolerabi

SC 13E3/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

PRER14A - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

10-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)